Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NLGN1 antisense RNA 1 (NLGN1-AS1)
- Target
- NLGN1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other (non-protein coding regulatory RNA)
01
Overview
NLGN1 antisense RNA 1 (NLGN1-AS1) is a cytoplasmic long non-coding RNA found to be upregulated in clear cell renal cell carcinoma. It mainly functions by sponging miR-136-5p, leading to increased expression of FZD4 and activation of the oncogenic Wnt/β-catenin signaling pathway, thereby promoting cancer cell proliferation. Knockdown of NLGN1-AS1 results in reduced proliferation and inhibition of this pathway, suggesting that NLGN1-AS1 may serve as a novel therapeutic target in cancers such as ccRCC. Its role is supported by both bioinformatic and experimental studies, but there are currently no approved drugs targeting NLGN1-AS1 directly[3][6].
- Other names
- NLGN1-AS1NLGN1 antisense RNA 1 (non-protein coding)
02
Mechanism of action
Knockdown (gene silencing) of NLGN1-AS1 decreases cell proliferation via upregulation of miR-136-5p and inhibition of the Wnt/β-catenin signaling pathway. Acts by sponging and regulating specific miRNAs (e.g., miR-136-5p) which in turn affect downstream target proteins like FZD4.
03
Biological functions
Regulation of gene expressionActing as a competing endogenous RNA (ceRNA) that binds miRNAs, especially miR-136-5pModulation of cell proliferationRegulation of the Wnt/β-catenin pathway in cancer
04
Disease associations
Cancer (clear cell renal cell carcinoma, ccRCC)Potentially other malignancies (no direct evidence from other indications yet)
05
Safety considerations
No major safety concerns reported; as a non-coding RNA, off-target effects of RNA-based therapies are theoretical and need further evaluationUnknown long-term impact on other physiological processes due to broad regulatory functions of lncRNAs
06
Interacting drugs
None identified in published literature as of September 2025
07
Biomarkers
Expression level of NLGN1-AS1 may be a biomarker for prognosis and disease progression in ccRCCPossible use of miR-136-5p expression as a functional biomarker in the context of NLGN1-AS1 targeting
Beyond the preview
Go deeper on NLGN1 antisense RNA 1 (NLGN1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLGN1 antisense RNA 1 (NLGN1-AS1).